Eli Lilly acquires biotech firm in new insulin venture
A new form of insulin drugs at Protomer Technoloigies caught the eye of Eli Lilly, which has bought the firm for a sum that could surpass USD 1bn (DKK 6.3bn).
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
US pharmaceutical company Eli Lilly has entered into an agreement to acquire biotech company Protomer Technologies for a price that could total more than USD 1bn. The final figure will be dependent on future performance and milestone payments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly welcomes competition for cheap insulin in US
For subscribers
